Observing Physiological Changes in Patients With Long-term Oxygen Therapy

Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Jul 25, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how long-term oxygen therapy (LTOT) affects patients with chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and pulmonary hypertension. The researchers want to see how certain body signals change when patients start using oxygen therapy and whether these changes differ for patients who are feeling weaker or those who are improving in their quality of life. To do this, they will collect data from 40 patients using a small device that measures light signals and body movement.

To participate in this study, you need to be at least 18 years old and have a chronic respiratory condition that requires oxygen therapy due to low oxygen levels in your blood. You should also be able to understand and communicate in German or French. If you join, you can expect to wear a device that records information about your body’s responses before and during your oxygen therapy. This research is important because it could help improve treatment for people with chronic lung diseases and enhance their quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18-year-old, and
• • Chronic respiratory disease including a) chronic obstructive pulmonary disease, b) interstitial lung disease, c) pulmonary hypertension, d) bronchiectasis, and
• • Prescribed new LTOT due to a chronic respiratory disease with resting and/or exertional hypoxemia, and
• • Able to speak/read/understand German or French, and
• • Willing and able to understand and provide signed informed consent
• Exclusion Criteria:
• • Pregnant or lactating women, or
• • Inability to follow the procedures/instructions of the study (e.g. due to language, psychological disorders, dementia, etc.), or
• • Patients having a subordination link to the investigators, or
• • Patients with isolated nocturnal oxygen therapy or LTOT prescription for a heart disease, sleep associated breathing disorder, neuromuscular disease or lung cancer, or
• • Known participation in another human research project (ClinO/HRO) that may affect the objectives of this study.